Pfizer, Inc. vs Sarepta Therapeutics, Inc. — Stock Comparison
Q·Score Breakdown
6.5
Neutral
Overall
4.4
Bearish
Quality
Health
Growth
Valuation
Sentiment
PFE
Strong profitability with 12% net profit margins.
⚠ analyst sentiment is cautious.
SRPT
Healthy balance sheet and financial position.
⚠ currently unprofitable (-32% margin).
Analyst Consensus
HOLD
Target $29.00 (+10.2%)
27 analysts
HOLD
Target $21.78 (+1.4%)
23 analysts
Fundamentals
PFE
SRPT
19.4×
Trailing P/E
—
9.4×
Forward P/E
7.2×
12.4%
Profit Margin
-32.5%
75.8%
Gross Margin
-7.4%
8.9%
ROE
-53.5%
-1.2%
Revenue Growth
-32.7%
—
Earnings Growth
—
0.39
Beta
0.28
—
Price / Book
—
$149.8B
Market Cap
$2.3B
$22 – $29
52-Week Range
$10 – $65
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →